Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetaminophen + butalbital + caffeine is a combination pharmaceutical product used primarily for the treatment of tension headaches (muscle contraction headaches). It combines three active ingredients with synergistic effects: acetaminophen, a non-opioid analgesic and antipyretic; butalbital, a short-to-intermediate acting barbiturate; and caffeine, a methylxanthine central nervous system stimulant. Acetaminophen provides pain relief by increasing the pain threshold, potentially through the inhibition of prostaglandin synthesis in the CNS. Butalbital acts as a sedative by modulating GABA-A receptors, helping to relieve the muscle tension and anxiety often associated with headaches. Caffeine serves as a vasoconstrictor, reducing blood flow in the brain and enhancing the analgesic efficacy of the other components. Originally developed and marketed under the brand name Fioricet, the combination is now widely available in generic forms and various strengths, typically 325 mg or 500 mg of acetaminophen, 50 mg of butalbital, and 40 mg of caffeine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + butalbital + caffeine.